DexCom, Inc. $DXCM Shares Acquired by BI Asset Management Fondsmaeglerselskab A S

Key Points

• BI Asset Management Fondsmaeglerselskab A S increased its stake in DexCom, Inc. by 47.2% during the first quarter, owning a total of 56,815 shares valued at $3,880,000.
• Other institutional investors also augmented their positions in DexCom, with Golden State Wealth Management LLC raising its stake by 211.2%.
• DexCom reported a 15.2% year-over-year revenue increase, generating $1.16 billion and an EPS of $0.48, surpassing analysts' estimates.

BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 47.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,815 shares of the medical device company's stock after acquiring an additional 18,221 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in DexCom were worth $3,880,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DXCM. Nuveen LLC purchased a new stake in DexCom during the first quarter valued at approximately $554,893,000. Jennison Associates LLC lifted its position in DexCom by 37.7% during the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock valued at $718,632,000 after acquiring an additional 2,879,489 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of DexCom by 171.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock worth $218,175,000 after buying an additional 2,015,971 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of DexCom by 2,371.4% in the first quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company's stock worth $136,220,000 after buying an additional 1,914,019 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of DexCom by 2.0% in the first quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company's stock worth $3,240,763,000 after buying an additional 925,882 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the transaction, the executive vice president directly owned 106,689 shares of the company's stock, valued at $9,494,254.11. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director directly owned 56,621 shares in the company, valued at $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 15,722 shares of company stock valued at $1,306,131. Corporate insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of research analyst reports. Argus assumed coverage on shares of DexCom in a report on Thursday, August 21st. They issued a "buy" rating and a $100.00 price target for the company. Morgan Stanley raised their price target on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Truist Financial started coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target on the stock. Robert W. Baird dropped their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Finally, Citigroup restated a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average target price of $99.89.

DexCom Price Performance

Shares of NASDAQ DXCM traded up $0.25 during trading on Tuesday, hitting $76.21. The company had a trading volume of 1,187,151 shares, compared to its average volume of 3,876,433. The stock has a fifty day simple moving average of $82.67 and a two-hundred day simple moving average of $79.68. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $29.89 billion, a price-to-earnings ratio of 52.99, a price-to-earnings-growth ratio of 1.72 and a beta of 1.43. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company's revenue for the quarter was up 15.2% on a year-over-year basis. During the same period last year, the firm posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.